Although much progress has been made in the understanding of the ontogeny and function of dendritic cells (DCs), the transcriptional regulation of the lineage commitment and functional specialization of DCs in vivo remains poorly understood. We made a comprehensive comparative analysis of CD8(+), CD103(+), CD11b(+) and plasmacytoid DC subsets, as well as macrophage DC precursors and common DC precursors, across the entire immune system. Here we characterized candidate transcriptional activators involved in the commitment of myeloid progenitor cells to the DC lineage and predicted regulators of DC functional diversity in tissues. We identified a molecular signature that distinguished tissue DCs from macrophages. We also identified a transcriptional program expressed specifically during the steady-state migration of tissue DCs to the draining lymph nodes that may control tolerance to self tissue antigens.
Although much progress has been made in the understanding of the ontogeny and function of dendritic cells (DCs), the transcriptional regulation of the lineage commitment and functional specialization of DCs in vivo remains poorly understood. We made a comprehensive comparative analysis of CD8(+), CD103(+), CD11b(+) and plasmacytoid DC subsets, as well as macrophage DC precursors and common DC precursors, across the entire immune system. Here we characterized candidate transcriptional activators involved in the commitment of myeloid progenitor cells to the DC lineage and predicted regulators of DC functional diversity in tissues. We identified a molecular signature that distinguished tissue DCs from macrophages. We also identified a transcriptional program expressed specifically during the steady-state migration of tissue DCs to the draining lymph nodes that may control tolerance to self tissue antigens.
The Immunological Genome Project (ImmGen) is a consortium of immunologists
and computational biologists from multiple institutes who have united to create an
exhaustive database of gene expression and regulatory gene networks across the
entire murine hematopoietic lineage using the same rigorously controlled data
generation pipeline. Utilizing this extensive database, we sought to define the
transcriptional profile and regulatory networks that control the dendritic cell (DC)
lineage development homeostasis and function.Discovered only fifty years ago, DC are the most recent addition to the
hematopoietic cell lineage[1]. DC
represent a small population of hematopoietic cells that share properties with
tissue macrophages (MF), including their localization in most tissues, their ability
to sample extracellular antigens, sense environmental injuries and contribute to the
induction of tissue immune response[1]. However, in contrast to MF whose main role is to scavenge
damaged cells or pathogenic microbes and promote tissue repair, the main function of
DC is to initiate antigen specific adaptive immune responses against foreign
antigens that breach the tissues [2]
as well as maintain tolerance to self-antigens [3]. The unique role of DC in adaptive immunity relies on their
ability to process and present self and foreign antigens in the form of MHC-class
II- and MHC class I-peptide complexes on the cell surface[4,5]
together with a superior ability to migrate to the tissue draining lymph nodes (LN)
[6] and co-localize with T
and B lymphocytes [7]. This makes DC
uniquely poised to control the induction of an antigen-specific immune response.
Controversies, however, still exist as to the overall distinction between DC and MF
due to partially overlapping phenotypse and functions and consequently the exact
contribution of MF and DC to tissue immune responses remains debated [8,9]DC consist of distinct subsets with different abilities to process antigens,
respond to environmental stimuli and engage distinct effector lymphocytes [10]. Classical DC (cDC) form the
predominant DC subset and are further subdivided into lymphoid tissue resident
CD8+ cDC and CD8− cDC [11]. Lymphoid tissue resident cDC subsets are
functionally specialized and CD8+ cDC excel in the
cross-presentation of cell associated antigens to CD8+ T cells,
whereas CD8− cDC are the most potent at stimulating
CD4+ T cells. The second major subset of DC is called
plasmacytoid DC (pDC). pDC are uniquely potent at producing large amounts of the
antiviral interferon alpha cytokine and initiate T cell immunity against viral
antigens [12]. Non-lymphoid tissue
DC also include two cDC subsets, the CD103+ cDC and
CD11b+ cDC [13]. Similar to lymphoid tissue CD8+ cDC,
non-lymphoid CD103+ cDC are efficient cross-presenters of
cell-associated antigens and are the most potent at stimulating
CD8+ T cells[10], but may also facilitate the induction of T regulatory cells in
the intestine [14].The successive steps that lead to DC lineage commitment in the bone marrow
are starting to be characterized. A myeloid precursors called macrophage and DC
precursor (MDP) [15] was recently
identified and shown to give rise to monocytes and to the common DC precursor (CDP)
[16]. CDP is a clonogenic
precursors that has lost monocyte/macrophage differential potential and gives rise
exclusively to pDC and cDC [17,18]. CDP also produce pre-cDC, a
circulating cDC restricted progenitor that has lost pDC differentiation potential
[16] and home to tissues to
differentiate locally into lymphoid tissue resident CD8+ and
CD8− cDC[16]
and non lymphoid tissue resident cDC [19]. Although, much progress has been made in our understanding of
DC ontogeny and function, the transcriptional regulation of DC lineage commitment,
diversification and functional specialization in vivo as well as
the relationship between lymphoid and non-lymphoid tissue DC remain poorly
understood. These questions remain unanswered due, in part, to the limited data
available to perform comprehensive, comparative analysis both vertically and
horizontally across the immune system.This study deciphers the transcriptional network of the bone marrow derived
DC precursors, the lymphoid tissue and non-lymphoid tissue DC as well as
non-lymphoid tissue DC in a migratory state. The results of this study help
characterize a DC-specific signature that distinguishes cDC from MF in tissues. Our
study also identifies the lineage relationship between different tissue DC subsets
as well as the predicted regulators of tissue DC diversity. Our results also uncover
a common transcriptional program expressed by all non-lymphoid tissue cDC that
migrated to the draining lymph nodes, regardless of their tissue or lineage
origin.
Results
Transcriptional characterization of the DC lineage
We characterized 26 distinct DC populations isolated from primary
lymphoid tissues, secondary lymphoid tissues and non-lymphoid tissues based on
cell surface expression thought to represent discrete DC subsets with
specialized immune function in vivo[13] (Table
1). Each subset was sorted to high purity according to the ImmGen
standard operating protocol. CD8+ and CD8−
cDC and pDC were isolated from the spleen, thymus and LN,
CD103+ and CD11b+ cDC were purified
from the lung, liver, small intestine and kidney and the epidermal LC were
isolated from the epidermis. Tissue migratory CD103+ and
CD11b+ DC were isolated from tissue draining LN.
Granulocyte macrophage precursors (GMP), macrophage DC precursors (MDP) and
common DC precursors (CDP) were purified from the bone marrow, whereas
circulating monocytes were isolated from the blood. Cell populations were double
sorted based on the cell surface markers described in Table 1 to reach more than 99% purity. The
final cytometric sorts (10,000 to 30,000 cells) were performed directly in
Trizol, frozen after 2 minutes, and sent to the ImmGen core team in Boston. RNA
was prepared from the Trizol lysate and hybridized to the microarray as
described in [21]. Expression
profiling data were generated on Affymetrix ST1.0 microarrays per ImmGen
pipeline, with data generation and quality control as detailed in [21]. The purified DC subsets were
isolated from laboratories located in New York (NY) and Boston (MA). One
population of spleen DC (population 1, sorted in NYC, NY) was sorted based on
MHC II and CD11c expression and lack of F4/80 and B220 expression and found to
be identical to spleen DC (population 2, sorted in Boston, MA) purified based
mainly on CD11c expression (Supplementary Note 2). To ascertain whether site or batch effects
may confound the signals, CD8+ and CD8−
spleen cDC were sorted independently at the two different locations (NY and MA).
The data showed excellent correlation within each subset, with little evidence
for lab-specific influences, in relation to the differences between
CD8− and CD8+ cDC subsets (Supplementary Fig.
1).
Table 1
Cell surface markers used to purify DC and DC precursor populations.
Population
Location
Phenotypical markers
Replicate Number
CD45
MHCII
CDllc
CD8
CD4
CDllb
CD103
F4/80
Gr1
B220
Sca1
cKit
Csf1r
Flt3
CD3
CD19
Ter119
Nk1.1
other
Lymphoid Tissue DC
Resident DC
CD8+
Skin Draining LN
+
+
+
-
-
-
-
-
-
-
-
3
Mesenteric LN
+
+
+
-
-
-
-
-
-
-
-
3
Spleen (1)- NY
+
+
+
-
-
-
3
Spleen (2)-MA
+
+
+
-
-
-
-
-
-
-
5
Thymus
+
+
+
+
-
-
+
-
-
-
-
-
-
3
CD8-
Skin Draining LN
+
+
-
+
+
-
-
-
-
-
-
3
Mesenteric LN
+
+
-
+
+
-
-
-
-
-
-
2
Spleen (1)- NY
+
+
-
+
-
-
6
Spleen (2)-MA
+
+
-
+
+
-
-
-
-
-
-
5
Spleen
+
+
-
-
+
-
-
-
-
-
-
3
Migratory DC
Mig CD103+
Skin Draining LN
hi
int
-
-
-
+
Langerin+
3
Mediastinal LN
hi
int
-
-
-
+
3
Mig CD11b+
Skin Draining LN
hi
int
-
-
+
-
Langerin-
3
Mediastinal LN
hi
int
-
-
+
-
3
Mig LC
Skin Draining LN
hi
int
-
-
+
-
Langerin+
3
pDC*
Spleen
+
+
+
+
+
-
-
-
3
Mesenteric LN
+
+
+
+
+
-
-
-
2
Skin Draining LN
+
+
+
+
+
-
-
-
3
Spleen
+
+
-
+
+
-
-
-
3
Non-Lymphoid Tissue DC
CD103+
Lung
+
+
+
-
+
5
Liver
+
+
+
-
-
-
+
-
2
Small Intestine
+
+
+
-
-
-
+
-
4
CD11b+
Lung
+
+
+
+
-
2
Liver
+
+
+
-
-
+
-
-
3
Small Intestine
+
+
+
-
-
+
-
+
7
Kidney
+
+
+
+
-
low
-
NKp46.1-
3
CD103+CD11b+
Small Intestine
+
+
+
-
-
+
+
-
-
4
LC
Skin
+
+
+
-
-
+
-
-
Langerin+
2
Precursors
GMP
Bone Marrow
-
-
-
-
hi
-
-
-
CD34+ CD16/32 hi
3
MDP
Bone Marrow
-
-
-
-
hi
+
+
-
-
3
CDP
Bone Marrow
-
-
-
-
lo
+
+
-
-
3
Monocyte
Blood
-
+
-
+
CD43-
3
DC precursors were isolated from the bone marrow, whereas differentiated DC
were purified from tissues. DC precursors and tissues DC were purified using
FACS based on the expression of the cell surface markers listed here and
according to the Immgen standard of operation procedures detailed in the
method section.
Spleen pDC include a CD8+ and CD8−
subset
Transcriptional control of DC lineage commitment
Myeloid lineage commitment to the mononuclear phagocyte lineage is
determined at the stage of the MDP, at which point erythroid, megakaryocyte,
lymphoid and granulocyte fates have been precluded [15,16,22]. DC
commitment occurs during MDP transition to CDP, with the loss of monocyte
potential [16], whereas
commitment to cDC occurs at the pre-cDC stage with the loss of pDC potential
[17,18].We probed the regulator expression pattern along the myeloid-DC lineage
tree to search for transcriptional activators and repressors that correlated
with each differentiation step, and thus identified groups of regulators induced
at different stages during DC differentiation (see materials and methods). The
first group was up-regulated (fold change [FC]≥1.5)
specifically during myeloid precursors commitment to the MDP potentially
influencing global DC and MF development (Fig.
1a
top). This group included the transcription factors
Sox4 and Taf4b known to play a role,
respectively, in cell fate and initiation of transcription. The second group of
transcripts was up-regulated (FC≥1.5) during GMP-MDP transition to CDP
but not during GMP-MDP transition to circulating monocytes (Fig.1a. bottom, left and middle panel)
potentially promoting lineage differentiation to DC over monocytes. This group
of regulators included the regulators Irf8, Bcl11a, Runx2, Klf8
and the zinc finger protein Zbtb46. A third group of regulator
transcripts was down-regulated (FC≤0.67) during GMP-MDP transition and
contained the TGF-β induced homeobox gene Tgif, the
transcription factor Tcfec and the E3 ubiquitine ligase
Trim13. To search for regulators that might contribute to
DC lineage diversification, we examined the expression of candidate gene
regulators during CDP differentiation to either pDC, lymphoid tissue
CD8+ cDC or lymphoid tissue CD8− cDC
(Supplementary Fig. 2,
Fig. 1c). CDP differentiation into pDC was associated with the
down-regulation of Id2, Zbtb46 and the TGF-β regulator
Cited2 suggesting that induction of these factors likely
contribute to lineage commitment to cDC differentiation. In contrast, CDP
differentiation to cDC was associated with the down-regulation of Irf8,
Tcf4, Runx2 and up-regulation of Batf3, Bcl6 and
Ciita transcription factors. We further identified
regulator transcripts up-regulated (FC≥1.5) in either
CD8+ or CD8− cDC. These transcripts
included expected genes such as the
CD8+CD103+-specific transcription
factor Irf8[19,23] as well as novel genes like
hox factor Pbx1 gene transcript shown to function during
definitive hematopoiesis in the fetal liver[24].
Figure 1
Transcription factor expression along the DC lineage. (a) Graphs
show the expression kinetics of transcriptional regulators up-regulated by 1.5
fold at the MDP level (i) and up-regulated (FC≥1.5) or
down-regulated (FC≤ 0.67) at the CDP level (ii) in
comparison to its precursor, downstream progeny or nearest neighbor. These
regulators were clustered by common patterns of gene expression across the GMP,
MDP, CDP, and monocyte families using the Express Cluster program.
(b) Heatmap representation of Fig. 1a and transcripts
up-regulated by at least 1.5 fold at each cellular checkpoint in comparison to
their nearest developmental neighbor (cDC versus pDC and CD8−
cDC versus CD8+ cDC) (Fig. S2). Genes are
log-transformed, normalized, and centered. Populations and genes were clustered
using pairwise centroid linkage with Pearson correlation. Red represents high
relative expression, while blue represents low relative expression.
*Replicates n ≥3 unless listed otherwise in Table 1.
Several transcription factors identified in our analysis have been shown
to control DC development. For example, pDC and cDC differentiation is dependent
on the zinc finger protein Ikaros[25], the cytokine Flt3 ligand and its receptor Flt3 (ref
[26]), whose expression
is partly controlled by Pu.1(Sfpi1) [27] and the transcription factor
Stat3, which is activated upon Flt3 signaling and mediates
Flt3 ligand-dependent DC differentiation[28]. Factors that regulate DC diversification are also
starting to be identified. The transcription factors Tcf4
(E2-2), Spib, and Irf8 have been shown to
control pDC differentiation [29]
whereas Bcl6 has also been shown to control cDC but not
pDC[30] development in
the spleen. The transcription factors Batf3 and Irf8, the
inhibitor of DNA (Id) 2 and the mammalian target of rapamycin
(Mtor)control the development of CD8+
and CD103+ cDC, while CD8− cDC
differentiation is controlled by the transcription factors Irf2,
Irf4[8] and
Notch2[20],
a factor that also controls the differentiation of intestinal
CD103+CD11b+ cDC[20]. Consistent with our finding that
Zbtb46 is expressed during transition to CDP and
down-regulated during CDP differentiation into pDC, two studies published this
week showed that Zbtb46 transcription factor is restricted to
cDC committed precursors and tissue cDC and is absent from pDC, monocytes,
macrophages and other myeloid and lymphoid cells[31,32]. Zbtb46 over-expression in bone marrow
progenitor cells inhibited granulocyte potential and promoted cDC development
strongly suggesting that Zbtb46 helps enforce cDC lineage
commitment[32] and may
serve as a useful marker to distinguish between cDCs and other tissue
phagocytes[31,32].Altogether, these results provide a map of known regulators but also
unknown potential regulators that accompany key cellular checkpoints of
DCpoiesis and help identify the molecular cues that control monocyte/DC lineage
differentiation as well as DC diversification in vivo.
Identification of a cDC core gene signature
One of the major challenges to understanding the exact contribution of
cDC versus MF in tissue immunity has been the lack of specific phenotypic
markers to define tissue cDC. We first ascertained whether cDC and MF sorted
based on published markers clustered as one or separate populations by
performing a principal component analysis (PCA) of the top 15% most
variable genes expressed by different steady-state leukocytes isolated from the
same organ in the steady-state (Supplementary Fig. 1d). These
results revealed that MF and cDC form distinct populations at the transcriptome
level.We then asked whether cDC expressed a set of transcripts that are
present in all cDC subsets, but absent from MF. As non-lymphoid tissue
CD11b+ cDC likely form a heterogeneous
population[8,9], we excluded non-lymphoid tissue
CD11b+ cDC from the comparative analysis and asked
whether lymphoid tissue CD8+ cDC and CD8−
cDC and non-lymphoid tissue CD103+ cDC shared specific cDC
transcripts that were absent from four prototypical MF populations profiled by
the ImmGen group as described in methods. Twenty-four transcripts were
differentially expressed (FC≥2; t-test false discovery rate
[FDR]≤0.05) in cDC and absent from MF as determined by
expression values below QC95, or the value at which the transcript has a
95% chance of being expressed (Fig.
2a, Table 2). This group of
transcripts form the “core cDC signature” and includes the
chemokine receptor Ccr7 shown to control cDC migration to the
draining lymph nodes[33], the
zinc finger protein Zbtb46, which is first up-regulated at the
CDP stage (Fig. 1a), and,
Flt3 that encodes the receptor for the cytokine Flt3 ligand
receptor known to control DC differentiation and homeostasis[22,34]. Although many of the genes transcripts enriched in cDC and
absent in MF were also found in other hematopoietic cell populations,
Zbtb46, Flt3, as well as Pvrl1 and
Anpep (Cd13) were significantly up-regulated in cDC
compared to all other hematopoietic cell subsets (Fig. S3; Table S1). Strikingly,
many transcripts had no identified role in cDC biology, such as
Kit, the receptor for kit ligand (stem cell factor) known
for its role in hematopoiesis as well as mast cell differentiation[35], and Btla
(CD272), an Immunoglobulin superfamily member that attenuates B cell and T cell
receptor-mediated signaling [36]. Btla was specifically up-regulated in
CD8+ CD103+ cDC populations in
comparison to CD8− cDCs (Fig.
2a-b, Fig. S3,
Table S1). Several transcripts were up-regulated (FC≥2;
t-test FDR≤0.05) in cDC compared to MF including multiple class II genes
and Dpp4 (CD26) (Fig. 2a, Table 3), whose role
in DC function remains unclear. Using flow cytometry, we confirmed that Flt3,
c-Kit, BTLA and CD26 were expressed at the protein level on spleen
CD8+, spleen CD8− cDC as well as
non-lymphoid tissue CD103+ cDC and absent from red pulp MF,
lung alveolar MF, peritoneal MF and microglia (Fig. 2b). Altogether these results identify a core DC signature that
helps distinguish tissue DC from MF in tissues.
Figure 2
Identification of gene uniquely expressed or up-regulated in cDC in comparison to
MF. (a) Heat map exhibits transcripts significantly up-regulated
(Student's t-test FDR ≤ 0.05; FC≥ 2) in lymphoid tissue
cDC and non-lymphoid tissue CD103+ cDC compared to four
prototypical MF populations. Transcripts expressed in cDC and absent in MF
according to the QC95 value are highlighted in yellow and form the core cDC
signature. Red represents high relative expression, while blue represents low
relative expression. Values are listed in Tables
2 and 3. (b)
Spleen, lung, kidney, lamina propria, liver, peritoneal cavity, and brain single
cell suspensions were analyzed by flow cytometry. Histograms show the expression
of Flt3, CD26, c0Kit, and BTLA in gated spleen CD8+, spleen
CD8−, tissue CD103+ cDC (red/blue
lines), and tissue MF (green lines) populations relative to isotype control
(gray lines). Data shown are representative of three different experiments.
MLN: mesenteric LN; SDLN: skin draining LN; SI: small
intestine. **Replicates n ≥3 unless listed
otherwise in Table 1.
Table 2
List of transcripts up-regulated in cDC and absent from MF
cDC vs MF
cDC Ave
MF Average
Adam19
1119+/-259.2
94.3+/-6.1
Amica1
702.6+/-216.9
45.5+/-3.1
Ap1s3
642.4+/-111.2
43.7+/-7.1
Ass1
905+/-234.2
69.8+/-2
Bcl11a
940.1+/-262.9
95.3+/-9.3
Btla
1481.7+/-413.3
49.4+/-3.9
Ccr7
1012+/-251.5
81.3+/-7.2
Flt3
3408.4+/-370.3
66.3+/-11
Gpr114
406.6+/-132.9
57.1+/-3.9
Gpr132
1007.6+/-127.9
84.1+/-5.2
Gpr68
289.4+/-61.4
52.5+/-4.8
Gpr82
67.7+/-18.2
11.7+/-0.8
H2-Eb2
782.2+/-371.1
43.4+/-5.5
Hmgn3
153.6+/-25.3
23.1+/-2.5
Kit
2368.3+/-375.7
67.7+/-6.1
Klri1
527.4+/-204.7
17.2+/-0.5
Kmo
1160.4+/-212.6
20.7+/-1.1
P2ry10
519.2+/-152.7
19.6+/-2.2
Pvrl1
475.6+/-54.3
74.4+/-6.1
Rab30
289.2+/-52.8
28.7+/-3.6
Sept6
1080.3+/-202.3
99.2+/-12.4
Slamf7
1727.4+/-145.6
31.7+/-5.2
Traf1
1044.4+/-224.5
51.6+/-2.8
Zbtb46
400.8+/-54.2
93.8+/-10.3
The transcriptome of cDC excluding non-lymphoid tissue
CD11b+ cDC subsets was compared to four MF
populations (red pulp MF, alveolar MF, peritoneal cavity MF and microglia)
to identify transcripts that were significantly (t-test FDR ≤ 0.05)
up-regulated by at least two fold and not expressed in MF according to the
QC95 value. Transcript expression average +/- the standard error of
the mean in cDC and MF are listed
Table 3
List of gene transcripts up-regulated in cDC
cDC vs MF
DC Ave
MF Average
Anpep (Cd13)
1682.8+/-197.7
87.1+/-20.7
Bri3bp
814.3+/-86.3
177+/-44.1
Cbfa2t3
1266.3+/-100.8
208.5+/-52.5
Ciita
1692+/-190.1
121.4+/-46.8
Cnn2
1884.8+/-271.2
230.7+/-54.7
Dpp4 (Cd26)
2567.1+/-360
72.3+/-29.6
Fgl2
1276.4+/-326
90.2+/-26.3
H2-Aa
13267.3+/-555.7
1632.6+/-1173.7
H2-Ab1
10299.7+/-490.6
1093.6+/-755.3
H2-DMb2
2491.8+/-305.6
400.5+/-67.6
H2-Eb1
7165.4+/-608
704.4+/-458.9
H2-Q6
1481.4+/-149.9
288+/-48.4
Haao
653.2+/-59.4
152.3+/-24.9
Jak2
2300+/-234.7
331.9+/-51.5
Napsa
1616.4+/-237
190.9+/-49.7
Pstpip1
475.1+/-42.7
104.4+/-16.4
Runx3
672.8+/-151.1
100.9+/-11.3
Spint2
773.6+/-166
139.4+/-8.4
Tbc1d8
2009.8+/-209.5
219.3+/-75.8
The transcriptome of cDC excluding non-lymphoid tissue
CD11b+ cDC subsets was compared to four MF
populations (red pulp MF, alveolar MF, peritoneal cavity MF, and microglia)
to identify transcripts that were significantly (t-test FDR ≤ 0.05)
up-regulated by cDC compared to MF. Transcript expression average
+/- the standard error of the mean in cDC and MF are listed.
Unique gene signatures characterize distinct tissue DC clusters
DC subsets are classified based on distinct cell surface markers and
different subsets exist in lymphoid and non-lymphoid tissues. To understand the
relationship between these different DC populations, we performed a PCA of the
top 15% most variable genes of lymphoid tissue pDC (spleen, skin
draining LN and mesenteric LN pDC), lymphoid tissue cDC (LN, spleen, thymic
CD8+ cDC; LN, spleen
CD8−CD4+ cDC; spleen
CD8-CD4-CD11b+cDC) and non-lymphoid
tissue CD103+ cDC (lung, liver, and small intestine)
populations. The main principal components identified three distinct DC clusters
(Fig. 3a). One cluster was formed by
lymphoid tissue CD8+ and non-lymphoid tissue
CD103+ cDC (Fig.
3a). A second cluster was formed by lymphoid tissue
CD8− cDC, whereas a third cluster was formed by pDC
(Fig. 3a). We used these clusters to
define specific gene expression signatures. The pDC cluster expressed 93 gene
transcripts absent from other cDC, whereas the two cDC clusters expressed 125
gene transcripts absent from pDC including Zbtb46, Pvrl1, and
Anpep (Cd13) (Fig. 3b;
Supplementary Fig. 4;
Supplementary Table 1). Further analysis of the two cDC subsets
revealed 28 gene transcripts shared by CD8+ and
CD103+ cDC and absent from other cDC (Fig. 3b; Supplementary Fig. 3-4; Supplementary
Table 1). CD8+ and CD103+ cDC
specific gene transcripts included Tlr3, the chemokine receptor
Xcr1. In agreement with their unique TLR3 expression,
CD8+ DC and
CD103+CD11b− DC share a superior
ability to respond to TLR3 ligand adjuvant [37-40]. In addition,
recent data revealed that CD8+ DC are also the only lymphoid
tissue DC subset that produces interferon lambda in response to the TLR3 ligand
Poly I:C [41] and similar
results were found for lung CD103+CD11b−
DC (Helft and Merad unpublished). Remarkably, Xcr1, which
controls CD8+ T effector cell differentiation in mice and
human [42,43], is expressed only in
CD8+CD103+ cDC across the entire
hematopoietic cell lineage (Supplementary Fig. 4c, Supplementary Table 1). Lymphoid tissue
CD8− cDC populations co-expressed core cDC gene
transcripts together with several monocyte and MF gene transcripts (Supplementary Fig. S4,
Supplementary Table 1), which is consistent with recent results from
our laboratory showing that CD8− cDC consist of two subsets
that differentially expressed MF related genes[20]. However, some genes including
Dscam (down syndrome cell adhesion molecule) were uniquely
expressed by CD8− cDC and absent from macrophages and
monocytes (Supplementary Fig.
4, Supplementary Table 1). Dscam is a molecule with enormous
molecular diversity which plays a role in axon guidance [44] and also functions as an immuno-receptor
able to recognize diverse pathogens in drosophila [45]
Figure 3
Unique gene signatures characterize distinct tissue DC clusters. (a)
PCA of the top 15% most variable genes across pDC,
CD8+ cDC, CD8− cDC and
CD103+ cDC transcripts. Replicates are shown.
(b) Heat map exhibits transcripts significantly (t-test FDR
≤ 0.05) up-regulated by at least two-fold and not expressed in the
exclusion population according to the QC95 value in pDC vs cDC, cDC vs pDC, and
CD8+/CD103+ cDC vs
pDC/CD8− cDC. Representative genes are listed on the
right. Full list is provided in Table S1. Red represents high
relative expression, while blue represents low relative expression.
(c–e) ImmGen fine modules consisting of
highly co-expressed transcripts and Ontogenet predicted regulators were
extracted from the expression dataset representing all hematopoietic cells.
Projection of (c) Module F150, (d) Module F156, and
(e) Module F152 across the immgen data and mean expression of
each module is shown (red colored squares represents high expression, while blue
represent low relative expression). The genes expressed in each module are
listed in italics below and predicted regulators are displayed in the color box.
Red represents predicted activators, while blue represents predicted repressors.
MLN: mesenteric LN; SDLN: skin draining LN; SI: small
intestine. *Replicates n ≥3 unless listed otherwise
in Table 1.
To dissect the gene architecture program of these subsets of DC, we
searched among the 334 fine modules of strongly co-expressed genes and predicted
regulators identified for the entire ImmGen compendium (http://www.immgen.org/ModsRegs/modules.html) to identify those
that were significantly up-regulated in specific DC subsets in comparison to the
rest of the ImmGen samples (material and methods) (Fig. 3c-e). Module 150 was significantly up-regulated in pDC
(p=4.77*10-11) and predicted
regulators of this module included Irf8, Stat2, Runx2, and
Tsc22d1 (Fig. 3c),
which were also expressed during CDP commitment to pDC (Fig. 1b). Module F156 was significantly up-regulated
in cDC (p=7.01*10-35) and enriched
in core cDC genes (p=4.18*10-10;
hypergeometric test) such as Zbtb46 and Pvrl1.
Predicted regulators of this module included Batf3 and
Relb (Fig. 3d), which
were also up-regulated during DC commitment to cDC (Fig. 1b). Module 152 was significantly up-regulated in
CD8+ CD103+ cDC
(p=1.34*10-25) and enriched in
CD8+ CD103+ DC transcript signature
(p<*10-13, hypergeometric test) such as
Tlr3, Xcr1 and Fzd1 (Fig. 3e). Irf8 and
Pbx1 also identified during CDP commitment to
CD8+ cDC (Fig. 1b)
were predicted regulators of this module (Fig.
3e). Module 154 was significantly up-regulated in
CD8− cDC
(p=1.08*10-15) and in intestinal
CD103+ CD11b+ cDC, a non-lymphoid
tissue cDC subset recently shown to share development properties with lymphoid
tissue CD8− cDC[20] (Supplementary Fig. 5). These modules together with the core gene
signature identify novel genes as well as potential regulators of DC functional
specialization in vivo.
The cDC core gene signature helps decipher tissue CD11b+
DC heterogeneity
Non-lymphoid tissue CD11b+ cDC remain the least well
characterized cDC subset both ontogenically and functionally. The small
intestine is populated by three phenotypically distinct cDC subsets that
differentially express the integrins CD103 and CD11b.
CD103+CD11b− cDC and
CD103+CD11b+ cDC are derived from the
CDP and pre-DC [46,47], require FLT3 ligand for their
development [47], migrate
efficiently to the draining LN [48] and are thought to represent cDC [49]. In contrast, the
CD103− CD11b+ subset derives from
circulating monocytes [46,47], develops independently of
FLT3 ligand, requires CSF-1R ligand for its development [47] migrates poorly to the draining LN
[48] and is thought to
relate more closely to MF than to cDC [49].To examine whether the core cDC signature identified above is
differentially expressed by these subsets, we purified
CD103+CD11b−,
CD103+CD11b+ and
CD103−CD11b+ small intestine (SI) cDC
subsets as well as lung, liver and kidney CD11b+ cDC, and
reran a PCA with the rest of the cDC subsets and with MF isolated from the
spleen, lung, brain and peritoneum. CD11b+ cDC subsets were
distributed across the PCA between the cDC and MF (Fig. 4a) and expressed a variable number of cDC core genes (Fig. 4b) indicating that non-lymphoid tissue
CD11b+ cDC as currently defined, represent a heterogenous
population.
Figure 4
Non-lymphoid tissue CD11b+ cDC are heterogeneous.
(a) PCA of the top 15% most variable transcripts
expressed by lymphoid tissue CD8+ cDC,
CD8− cDC, non-lymphoid tissue CD103+
cDC, non-lymphoid tissue CD11b+ cDC, epidermal LC and MF.
Population means are shown. Population color labels displayed next to heatmap
column labels of Fig 4c. (b) Graph show percentages of core cDC
transcripts (identified in Fig. 2) that are
up-regulated (FC≥2) in CD11b+ cDC subsets and red
pulp MF. (c) Heat map indicates the relative expression of cDC and
MF transcripts in each cDC population. Red represents high relative expression,
while blue represents low relative expression. (d) Small intestine
single cell suspensions were analyzed by flow cytometry for core cDC genes. Dot
plot shows the expression of CD103 and CD11b on
DAPI−CD45+CD11c+MHCII+
lamina propria cDC. Histograms show the expression of Flt3, CD26, c-Kit, and
BTLA among CD103+CD11b− cells,
CD103+CD11b+ F4/80−
cells and CD103+CD11b+
F4/80+ cells. Data shown are representative of three
different experiments. MLN: mesenteric LN; SDLN: skin draining LN; SI:
small intestine. LC: Langerhans cells.. *Replicates n
≥3 unless listed otherwise in Table
1.
CD103+CD11b− SI cDC clustered with
the CD8+ CD103+ cDC, whereas lamina
propria CD103+CD11b+ SI cDC clustered near
lymphoid CD8− cDC and did not express CD8+
CD103+ cDC unique transcripts (Fig. 4a, Supplementary Fig. 6). Accordingly,
CD103+CD11b− SI cDC expressed all
CD8+CD103+ cDC specific transcripts
identified (Fig. 3), including
Fzd1 a Wnt receptor signaling which controls
β-catenin activation and translocation to the nucleus (Supplementary Fig. 4, 6).
Fzd1 was expressed specifically in
CD103+CD11b− SI cDC and was absent
from CD103+CD11b+ cDC and
CD103−CD11b+ SI cDC (Supplementary Fig. 6).
β-catenin activation and translocation to the nucleus can control the
ability of DCs to promote T cell tolerance in the intestine[50]. It will be important to examine the
contribution of Fzd1 and
CD103−CD11b+ SI cDC to T cell immune
modulation in the gut.In contrast, the CD103−CD11b+ cDC
clustered close to MF and away from other DC (Fig.
4a). Consistent with the PCA results, we found that
CD103+CD11b− and
CD103+CD11b+ SI DC expressed
100% of the core cDC genes as well as the cDC specific proteins c-Kit,
Flt3, BTLA and CD26 on the cell surface (Fig.
4b-d, Fig.
S6) suggesting that these two subsets belong to the DC lineage. In
contrast, CD103−CD11b+ cDC clustered close
to MF and away from cDC, they expressed only 40% of the core cDC genes
and lacked the cDC proteins Kit, Flt3, BTLA and CD26 on the cell surface (Fig. 4b-d; Supplementary Fig. 6) suggesting
that small intestine CD103−CD11b+ cDC
belong to the MF lineage. Accordingly, a focused analysis of MF-associated
transcripts indicated that the CD103-CD11b+ cDC SI
population clustered with MF (Gautier et al., in preparation). Altogether, these
results establish that the current DC phenotypic definition, which is based on
MHC class II and CD11c expression, is not sufficient to identify tissue DC; and
the use of the cDC gene signature provides a new means to distinguish
CD11b+ cDC from MF in non-lymphoid tissues.
Migratory DC display a unique transcriptional signature
Tissue draining LN contain blood-derived DC that include pDC,
CD8+ cDC and CD8− cDC also called LN
resident DC as well as non-lymphoid tissue CD103+ cDC and
CD11b+ cDC that have migrated from the drained tissue
also called “tissue migratory cDC” [6]. The mechanisms that control non-lymphoid
tissue cDC migration and function in the draining LN in response to tissue
injury or tissue immunization are starting to be unraveled; however, far less is
known about the gene program that controls cDCs ability to leave peripheral
tissues and migrate to the draining LN or the gene regulators that control
migratory cDC immune function in the non-inflamed state [6]. Here we analyzed the transcriptional
program of tissue cDC prior to their migration to the draining LN (parent DC
population) and upon migration to the LN as well as LN resident cDCs.
Strikingly, we found that migratory cDC segregated together irrespective of
their cellular or tissue origin and away from parent cDC populations that
populate the drained tissue (Fig. 5a) and
expressed a very similar transcriptional program (Fig. 5b-e). CD11b+ migratory cDC clustered
together with CD103+ migratory cDC suggesting that among
tissue CD11b+ cDC those that migrated in the steady state may
represent the “bonafide” cDC. In addition, we found that in
contrast to tissue CD11b+ cDC, which expressed moderate
amounts of the DC specific gene Flt3, migratory
CD11b+ cDC always expressed high Flt3
levels. Specifically, epidermal Langerhans cells (LC), which develop
independently of Flt3 and Flt3L [19] and express very low amounts of Flt3 in
tissue, dramatically up-regulated Flt3 transcripts once they
reach the LN (Supplementary
Fig. 7), suggesting that Flt3 plays a critical role in the
homeostasis or function of steady state migratory cDC.
Figure 5
Tissue migratory cDC up-regulate a unique gene signature regardless of tissue or
cellular origin. (a) PCA of top 15% most variable
transcripts expressed by lymphoid tissue resident CD8+ cDC
and CD8− cDC, non-lymphoid tissue CD103+
cDC, non-lymphoid tissue CD11b+ cDC, epidermal Langerhans
cells (LC), migratory (Mig) LC isolated from the skin draining LN, and migratory
CD103+ and CD11b+ cDC isolated from
skin-draining and lung-draining LN. Population means are shown. Fold change-fold
change comparison of gene expression between (b) migratory
CD103+ cDC and CD11b+ cDC and
non-lymphoid tissue resident CD103+ and
CD11b+ cDC, (c) migratory
CD103+ cDC and CD11b+ cDC compared to
lymphoid tissue resident CD8+ cDC and CD8−
cDC, and (d) migratory LC versus epidermal LC. Red highlights
transcripts significantly (FC≥2; t-test p≤ 0.05) increased by at
least two–fold, whereas blue highlights those significantly decreased
(FC≤ 0.5; t-test p≤ 0.05) in all population comparisons.
(e) Heat map representation of the transcripts in fold-change
fold-change plots from (b-d). Genes listed to the right are
up-regulated by at least five-fold. Transcripts not expressed in steady state
tissue cDC according to the QC95 value in migratory DC vs resident cDC are
highlighted in red. Genes in heatmap are listed in Table S2. In heatmap, red
represents high while blue represents low relative expression LuLN: lung
draining LN; SDLN: skin draining LN; SI: small intestine, LC: Langerhans
Cell. *Replicates n ≥3 unless listed otherwise in
Table 1.
We also found that tissue migratory cDC up-regulated some gene
transcripts dedicated to the dampening of immune responses (Fig. 6). As dampening genes can also be up-regulated
in response to injury, we further compared steady state migratory cDC with Poly
I:C activated cDC (Fig. 6a). As expected,
Poly I:C activated and steady state tissue migratory cDC up-regulated the
co-stimulatory gene transcript Cd40, previously reported on
steady state migratory LC[51]
(Fig. 6a); however, steady state
migratory cDC failed to up-regulate inflammatory cytokine transcripts (Fig. 6b) and expressed higher levels of
immunomodulatory transcripts compared to Poly:I:C activated cDC (Fig. 6a). Immunomodulatory transcripts up-regulated in
steady state migratory cDC included genes known to suppress T cell function
either directly such as Cd274 (Pd-l1)
[52], or via the
production or activation of immunosuppressive cytokines such as the
TGF-β activating integrin Itgb8[53]. Other up-regulated transcripts encoded proteins known
to reduce DC activation and cytokine production including
Socs2, a TLR–responsive gene which regulates DC
cytokine release via STAT3 modulation[54], Pias3, also known to modulate STAT3
phosphorylation and NF-κB expression[55], and Cd200, a protein known to reduce
pro-inflammatory DC activation upon binding to its receptor, which is also
expressed on DC[56].
Furthermore, steady state migratory cDC up-regulated transcripts important in
reducing DC survival including cell death receptor Fas
[57,58]. Using flow cytometry and immunofluorescence analysis,
we confirmed protein expression of Fas, Cd200, Pd-l1, and
Pias3 and the co-stimulatory molecule Cd40
in steady state tissue migratory cDC (Fig.
6c-d). Based on these data we will speculate that cDC that leave the
non-lymphoid tissues in the steady state upregulate a transcriptional
immunomodulatory program that may prevent the induction of adaptive immune
response to self- tissue antigens. The functional relevance of the
immunomodulatory migratory DC signature needs to be confirmed
experimentally.
Figure 6
Tissue migratory cDC express immune dampening genes in the steady state. Bar
graphs show fold changes of (a) immunomodulatory and Cd40
transcripts, (b) inflammatory transcripts in purified lung resident
CD103+ cDC (gray), Poly: I:C treated lung
CD103+ cDC (white), LN tissue resident
CD8+ cDC (black) and lung migratory (Mig)
CD103+ cDC (red) over the minimum value of the four
compared populations. (c) LN single cell suspensions were analyzed
by flow cytometry. Histograms show the expression of CD200, FAS, CD40, and PD-L1
in gated
DAPI−CD45+CD11chiMHCIIInt
resident cDC (blue) and
DAPI−CD45+CD11cintMHCIIhi
migratory cDC (pink) compared to isotype controls (gray). (d) LN
resident cDC (left panels) and migratory cDC (right panels) were sorted,
cytospun, and stained with secondary mAb alone (top panels) or anti-Pias-3 mAb
(bottom panels). Magnification (63×). LuLN: lung draining LN;
SDLN: skin draining LN; SI: small intestine, LC: Langerhans Cell.
Data shown are representative of three different experiments. *Replicate
n ≥3 in graphs unless listed otherwise in Table 1.
Discussion
This study provides the first comprehensive comparative analysis of DC
precursors and tissue DC transcriptome across the entire immune system. The results
of this study help identify: a transcriptional network that accompanies DC lineage
commitment and diversification; a DC-specific signature that distinguishes cDC from
MF in tissues; the relationship between lymphoid and non-lymphoid tissue DC subsets
and predicted regulators of DC diversity; and a transcriptional immunomodulatory
program expressed specifically during steady state tissue DC migration to the
draining LN.To gain knowledge of the transcriptional network that controls myeloid
commitment to the DC lineage, we analyzed the transcriptional network associated
with three key DC differentiation checkpoints: CMP ➔MDP, MDP ➔ CDP
and CDP ➔ pDC CD8+ cDC or CD8− cDC.
This analysis identified a group of transcriptional activators that include
Zbtb46, Runx2, Bcl11a and Klf8 that rose
specifically during MDP commitment to CDP but not monocytes suggesting their
potential key role in driving myeloid commitment to the DC restricted precursors and
away from monocytes in vivo. We also characterized the
transcriptional networks that accompany CDP differentiation into pDC,
CD8+ cDC and CD8− cDC subsets and identify
several gene candidates that may drive DC lineage diversification in
vivo.One of the main controversies in the DC literature is the distinct
contribution of cDC versus MF to tissue immunity. This confusion is partly a
consequence of the paucity of markers available to distinguish between these two
cell types leading researchers to use promiscuous markers such as MHC class II,
CD11c and F4/80 to assess cDC or MF specific function[9]. We identified a core cDC gene signature
shared by lymphoid tissue CD8− and CD8+ cDC,
and non-lymphoid tissue CD103+ cDC and absent from tissue MF.
cDC-specific transcripts included the gene coding for Zbtb46, Flt3, Kit and CCR7.
The identification of the Kit transcript as part of the cDC gene
specific signature is surprising, as Kit and its ligand have never
been shown to play an intrinsic role in cDC development in vivo.
Future studies will be needed to identify the role, if any, of Kit in DC
differentiation, function and homeostasis in vivo. Importantly, the
use of the cDC gene signature helped delineate the heterogeneity of non-lymphoid
tissue CD11b+ cDC and identify a contaminating MF population,
which could not have been detected using phenotypical markers currently used to
define DC populations in vivo.We also established that among cDC, lymphoid tissue CD8+
cDC and non-lymphoid tissue CD103+ cDC shared a gene signature,
regardless of the tissue environment in which they reside. CD8+
CD103+ cDC gene signature was absent from the rest of DC
including pDC, CD8− cDC and CD103− cDC in
these same tissues. These results establish CD8+
CD103+ cDC as a distinct lineage subset and identify the gene
regulators that may drive their differentiation, homeostasis and function. Using the
novel algorithm termed Ontogenet developed for the ImmGen dataset (Jojic et al, in
preparation), we identified modules of strongly co-expressed genes that were
specifically and differentially expressed in each DC subset. Specifically we show
that modules F150, F156 and F152 are up-regulated in pDC, cDC and
CD8+ CD103+ cDC respectively and identify
candidate regulatory programs that predict their expression pattern and therefore
may drive DC functional specialization in vivo.Strikingly, we found that regardless of tissue or cellular origin,
non-lymphoid tissue CD103+ cDC and CD11b+ cDC
as well as epidermal LC that migrate to the draining LN in the steady state
up-regulate a shared gene signature. Some of the highest up-regulated transcripts
are implicated in DC production of immunosupressive cytokine, the dampening of DC
activation and reduction of DC survival that is known to lead to the dampening of T
cell activation. These results are consistent with the potential role of steady
state migratory cDC in the induction or maintenance of T regulatory
response[3] and identify
candidate molecules that may participate in the control tolerance to self-antigens
in vivo.The results of this study provide a comprehensive characterization of the DC
lineage transcriptional network and should help the development of novel genetic
tools such as inducible gene regulation in vivo and lineage tracing
of genetically marked defined myeloid precursor populations to further comprehend
the developmental complexity of the phagocyte system. Moreover, the availability of
the ImmGen datasets will now permit further investigations into DC gene expression
networks and help unravel the transcriptional program that control DC function in
the steady and injured state.
Methods
Mice
All cells analyzed in this study were obtained from six-week-old male
C57BL/6J mice purchased from Jackson Laboratory with exception of LC and Mig LC
which were isolated from Langerin EGFP C57BL/6J mice [59]. All mice were housed in specific
pathogen–free facilities at the Mount Sinai School of Medicine facility.
Experimental procedures performed in mice were approved by the Animal Care and
Use Committee of the Mount Sinai School of Medicine.
Cell sorting and flow cytometry
All cells were purified using the ImmGen Standardized Sorting protocol
and antibodies listed on http://www.ImmGen.org. Sorting
was performed at the Mount Sinai Flow Cytometry Shared Resource Facility using
the Aria II (BD) or Influx (BD). Marker combination used to sort specific
populations are available on http://www.ImmGen.org.
Multiparameter analysis of stained cell suspensions were performed on LSRII (BD)
and analyzed with FlowJo software (Tree Star, Inc). Monoclonal antibodies (mAbs)
specific to mouseCD8 (clone 53-6.7), CD4 (clone L3T4), CD45 (clone 30-F11),
CD11c (clone N418), CD11b (clone M1/70), I-A/I-E (clone M5/114.15.2), CD103
(clone 2E7), CD117/c-Kit (clone 2B8), CD135/Flt3 (clone A2F10), CD26 (clone
H1940112), BTLA/CD272 (clone 6F7), CD40 (clone HM40-3), CD95/Fas (clone Jo2),
CD200 (clone OX90), PD-L1/CD274 (clone MIH5), and the corresponding isotype
controls were purchased from eBioscience or BD.
Cytospin and immunofluorescence of sorted cells
Viable sorted cells isolated according to MHCII and CD11c expression
were sorted, Cytospun onto glass slides, and dried overnight. Slides were fixed
for 1 hr with 4% paraformaldehyde in PBS, blocked with 10% goat
serum in 0.1% Triton/0.1% BSA in PBS for 1 hr, then stained for
48 hrs at 4°C followed by 1 hr incubation at room temperature (RT) with
the goat anti- mousePias3 mAb (Sigma, clone P0117) at 1:2000 dilution.
Secondary goat anti-mouseAlexa Fluor594 (Invitrogen) was added to slides for 1
hr at RT. Slides were mounted with DAPI in Fluoro-gel with Tris buffer (Electron
Microscopy Sciences). Images were acquired at 63× using the Zeiss
Axioplan2IE with a Zeiss AxioCam MRc and analyzed using the Zeiss AxioVision
software.
Microarray analysis, normalization and dataset analysis
RNA was prepared from sorted cell populations from C57BL/6J mice using
Trizol reagent as described[60].
RNA was amplified and hybridized on the Affymetrix Mouse Gene 1.0 ST array
according to the manufacturer's procedures. Raw data for all populations
were preprocessed and normalized using the RMA algorithm [61] implemented in the “Expression
File Creator” module in the GenePattern suite [62]. All datasets have been deposited at the
National Center for Biotechnology Information/Gene Expression Omnibus under
accession number GSE15907 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE15907).
RNA processing and microarray analysis with the Affymetrix MoGene 1.0 ST array
was prepared according to ImmGen standard operating procedures (http://www.immgen.org/Protocols/ImmGen).
Identification of transcription factors associated with DC lineage commitment
and diversification
Dataset was filtered for regulators [63] with a coefficient of variation (CV) <0.5
within population replicates. MDP regulators were selected for transcripts
expressed 1.5 fold greater than GMP and CDP. CDP regulators were filtered for
transcripts expressed 1.5 greater or 0.67 fold less than the precursors MDP
and/or GMP. The “MDP and/or GMP” classification allows inclusion
of transcripts that may be increasing in the MDP population as well and thus
still informative. These were further filtered for expression at least 1.5 fold
greater or 0.67 fold less than the nearest neighbor monocytes to find
up-regulated or down regulated transcripts important in the DC lineage alone.
Gene lists were input into the GenePattern module ExpressCluster (http://cbdm.hms.harvard.edu/resources.html) to identify patterns
of expression across the GMP, MDP, CDP and monocyte populations.Dataset was filtered for regulators with a CV <0.5 within these
populations [63]. Differentiated
DC subsets were compared to their nearest developmental neighbor using a two-way
analysis of variance Student's t-test on normalized expression data
corrected with the Benjamini and Hochberg false discovery rate <0.05 and
further selected for transcripts up-regulated by at least 1.5 fold within each
organ. Thus, pDC were compared to
CD8+/CD8− cDC and
CD8+ cDC were compared to CD8− cDC
within spleen, MLN, and SDLN DC and filtered for transcripts up-regulated at
least 1.5 fold in each comparison. pDC and cDC were then compared to their
precursor CDP to identify transcripts decreased at least 1.5 fold from the
precursor. Transcripts up-regulated or expressed at the same level as CDP (red
arrow) whereas transcripts downregulated compared to the CDP (blue arrows) are
shown.
Generation of the cell specific gene signatures
Differentially expressed transcripts were calculated using an unpaired
two-way analysis of variance Student's t-test on normalized expression
data. The t-test was controlled for multiple hypothesis using Benjamini and
Hochberg false discover rate <0.05. The dataset was then filtered for
those probes for which the fold change of any single population mean of the
inclusion group over any single population mean of the exclusion group was
≥2 to create signatures of up-regulated transcripts. The dataset was
further filtered for transcripts in which, the exclusion populations had an
expression value less than the QC value of 95, or the level at which each
population would have a predicted 95% certainty of expressing the gene.
These gene signatures were also analyzed for variance across all steady-state
leukocyte populations using the ANOVA command “aov “in R. Data
were log transformed before analysis. Post-hoc pairwise Student's t-
tests were run on each population corrected for multiple hypotheses testing
using the Bonferroni adjustment. Data are provided in Table S1.
Generation of the migratory DC gene signature
Dataset was filtered for transcripts with a CV <0.5 within
population replicates. For creation of the migratory DC signature, the migratory
LC, lung CD103+ cDC, and lung CD11b+ cDC samples were directly
compared to their tissue resident equivalents and selected for transcripts with
a FC≥2 which satisfied the Student's t-test p <0.05. To
remove any potential signature that could be created by the lymph node
environment, the remaining transcripts were compared in the migratory vs
resident SDLN populations again selecting for transcripts at least 2 fold
increased which satisfied the t-test p <0.05. This same method was
applied to transcripts with a FC ≤ 0.5 which satisfied the t-test p
<0.05 to identify a down-regulated signature. This analysis was
performed in the GenePattern module Multiplot [64].
Generation of gene modules and prediction of module regulators
The expression data normalization was done as part of the ImmGen
pipeline, March 2011 release. Data were log2 transformed. For gene symbols
represented on the array with more than one probeset, only the probeset with the
highest mean expression was retained. Of those, only the 7996 probesets
displaying a standard deviation higher than 0.5 across the entire dataset were
used for the clustering.Clustering was performed by Super Paramagnetic Clustering [65] with default parameters,
resulting in 80 stable clusters. The remaining unclustered genes were grouped
into a separate cluster (C81). Those are referred to in the text as coarse
modules C1-C81. Each coarse cluster was further clustered by hierarchical
clustering into more fine clusters, resulting in 334 fine modules, referred to
in the text as fine modules F1-F334. The expression of each gene was
standardized by subtraction of the mean and division by its standard deviation
across all dataset. Replicates were averaged. Mean expression of each module was
projected on the tree. Expression values are color coded from minimal (blue) to
maximal (red).A novel algorithm termed Ontogenet was developed for the ImmGen dataset
(Jojic et al, in preparation). Ontogenet finds a regulatory program for each
coarse and fine module, based on regulators expression and the structure of the
lineage tree. One sided two-sample Kolmogorov-Smirnov test was applied to the
mean expression of each of the ImmGen fine modules to identify modules with
significantly induced expression in specific cell groups. The cell groups were
pDC, cDC, CD8- DC and CD8+/CD103+. Background for each was the
rest of the ImmGen samples. Benjamini Hochberg FDR <= 0.05 was
applied to the p-value table of all four groups across all fine modules.
Hypergeometric test for two groups was used to estimate the enrichment of ImmGen
fine modules for the four gene signatures. Benjamini Hochberg FDR
<= 0.05 was applied to the p-value table of all four groups
across all fine modules.
Data analysis and visualization tools
Signature transcripts were clustered and visualized with
“HeatMap Viewer” or the “Hierarchical
Clustering” tool using Gene Pattern [64]. For hierarchical clustering, data were log scaled,
centered around the mean, and clustered using Pearson correlation as a measure
and pairwise complete-linkage clustering as a linkage type. Data were centered
on rows before visualization. Principal component analysis (PCA) was performed
using the Immgen PopulationDistances PCA program (http://cbdm.hms.harvard.edu/resources.html). Where indicated,
the PCA program was used to identify the 15% most differentially
expressed genes among subsets by filtering based on a variation of analysis
using the geometric standard deviation of populations to weight genes that vary
in multiple populations. Data were log transformed, gene and subset normalized,
and filtered for transcripts with a CV<0.5 in each set of sample
replicates before visualization. Fold change vs fold change and fold change vs t
test p-value were visualized using the “Multiplot” module from
Gene Pattern [64]. Graphs of
individual genes were created utilizing Prism Software.
Authors: Matthew M Meredith; Kang Liu; Guillaume Darrasse-Jeze; Alice O Kamphorst; Heidi A Schreiber; Pierre Guermonprez; Juliana Idoyaga; Cheolho Cheong; Kai-Hui Yao; Rachel E Niec; Michel C Nussenzweig Journal: J Exp Med Date: 2012-05-21 Impact factor: 14.307
Authors: Deepali Malhotra; Anne L Fletcher; Jillian Astarita; Veronika Lukacs-Kornek; Prakriti Tayalia; Santiago F Gonzalez; Kutlu G Elpek; Sook Kyung Chang; Konstantin Knoblich; Martin E Hemler; Michael B Brenner; Michael C Carroll; David J Mooney; Shannon J Turley Journal: Nat Immunol Date: 2012-04-01 Impact factor: 25.606
Authors: Olga Schulz; Elin Jaensson; Emma K Persson; Xiaosun Liu; Tim Worbs; William W Agace; Oliver Pabst Journal: J Exp Med Date: 2009-12-14 Impact factor: 14.307
Authors: Katharina Hochheiser; Christoph Heuser; Torsten A Krause; Simon Teteris; Anissa Ilias; Christina Weisheit; Florian Hoss; André P Tittel; Percy A Knolle; Ulf Panzer; Daniel R Engel; Pierre-Louis Tharaux; Christian Kurts Journal: J Clin Invest Date: 2013-09-03 Impact factor: 14.808
Authors: Hideki Nakano; Timothy P Moran; Keiko Nakano; Kevin E Gerrish; Carl D Bortner; Donald N Cook Journal: J Immunol Date: 2015-03-13 Impact factor: 5.422
Authors: Ruth A Franklin; Will Liao; Abira Sarkar; Myoungjoo V Kim; Michael R Bivona; Kang Liu; Eric G Pamer; Ming O Li Journal: Science Date: 2014-05-08 Impact factor: 47.728
Authors: Terhi S Savinko; Vicky L Morrison; Liisa M Uotila; C Henrik J Wolff; Harri T Alenius; Susanna C Fagerholm Journal: J Invest Dermatol Date: 2015-04-28 Impact factor: 8.551
Authors: Kutlu G Elpek; Viviana Cremasco; Hua Shen; Christopher J Harvey; Kai W Wucherpfennig; Daniel R Goldstein; Paul A Monach; Shannon J Turley Journal: Cancer Immunol Res Date: 2014-03-31 Impact factor: 11.151